Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis
Open accessAbstract
INTRODUCTION: Patients with CF experience pulmonary exacerbations. These are often initially empirically treated with intravenous antibiotics, with antibiotic choice refined after susceptibility testing. METHODS: We completed a 5-year retrospective review of children attending the Paediatric CF Unit, Nottingham. The respiratory sampling, antibiotic prescribing and susceptibility testing guidance were audited. Episodes were classified according to the concordance between the antibiotics prescribed and antibiotic susceptibility testing. RESULTS: Of 52 patients who had previously isolated Pseudomonas aeruginosa, 103 antibiotic courses were commenced that coincided with an isolation of P. aeruginosa. P. aeruginosa was fully susceptible, partially susceptible or fully resistant on 33%, 44.7% or 16.5% of occasions respectively. The antibiotic prescriptions were never changed following antibiotic susceptibility testing. We found no association between change in FEV(1) (p=0.54), change in BMI (p=0.12) or time to next exacerbation (p=0.66) and concordance between antibiotic susceptibility and the antibiotics administered. CONCLUSION: This study contributes to mounting evidence questioning the utility of routine antibiotic susceptibility testing.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There is no detectable relation between antibiotic susceptibility of cultured organisms and clinical response to therapy in exacerbations, even in cystic fibrosis.
“there is no detectable relation between antibiotic susceptibility of cultured organisms and clinical response to therapy in exacerbations, even in cystic fibrosis.”
From The microbiome and critical illness (2016) · cites this paper as [140]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Emerson, J., Rosenfeld, M., McNamara, S., Ramsey, B. W., & Gibson, R. L. (2002) · Pediatric Pulmonology · doi:10.1002/ppul.10127 · Cited by 1,009 · see citing works
Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations
Flume, P. A., Mogayzel, P. J., Robinson, K. A., Goss, C. H., Rosenblatt, R. L., Kuhn, R. J., & Marshall, B. C. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200812-1845pp · Cited by 736 · see citing works
Failure to Recover to Baseline Pulmonary Function after Cystic Fibrosis Pulmonary Exacerbation
Sanders, D. B., Bittner, R. C. L., Rosenfeld, M., Hoffman, L. R., Redding, G. J., & Goss, C. H. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200909-1421oc · Cited by 520 · see citing works
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Hewer, S. C. L., & Smyth, A. R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004197.pub4 · Cited by 324 · see citing works
Self-citationSmith, A. L., Fiel, S. B., Mayer-Hamblett, N., Ramsey, B., & Burns, J. L. (2003) · Chest · doi:10.1378/chest.123.5.1495 · Cited by 307 · see citing works
Ratjen, F. A., Munck, À., Kho, P., et al. (2009) · Thorax · doi:10.1136/thx.2009.121657 · Cited by 291 · see citing works
Aaron, S. D., Vandemheen, K. L., Ferris, W., Fergusson, D. A., Tullis, E. D., Haase, D. A., Berthiaume, Y., Brown, N. E., Wilcox, P., Yozghatlian, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67060-2 · Cited by 238 · see citing works
Acquisition and eradication ofP. aeruginosain young children with cystic fibrosis
Douglas, T. A., Brennan, S. R., Gard, S., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00043108 · Cited by 167 · see citing works
British Society for Antimicrobial Chemotherapy
(2019) · Palgrave Macmillan UK eBooks · doi:10.1057/978-1-349-95943-3_200 · Cited by 163 · see citing works
Aaron, S. D., Ferris, W., Ramotar, K., Vandemheen, K. L., Chan, F., & Saginur, R. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.11.4172-4179.2002 · Cited by 145 · see citing works
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Hewer, S. C. L., & Smyth, A. R. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004197.pub3 · Cited by 80 · see citing works
Self-citationLee, T. W. R., Brownlee, K. G., Denton, M., et al. (2004) · Pediatric Pulmonology · doi:10.1002/ppul.10401 · Cited by 75 · see citing works
Duration of intravenous antibiotic therapy in people with cystic fibrosis
Plummer, A., Wildman, M. J., & Gleeson, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006682.pub5 · Cited by 71 · see citing works
Moskowitz, S. M., Foster, J. M., Emerson, J., et al. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki338 · Cited by 48 · see citing works
Pulmonary Exacerbations in Cystic Fibrosis
Marshall, B. C. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2401009 · Cited by 46 · see citing works
Etherington, C., Hall, M. J., Conway, S., et al. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm481 · Cited by 28 · see citing works
Duration of intravenous antibiotic therapy in people with cystic fibrosis
Plummer, A., & Wildman, M. J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006682.pub3 · Cited by 12 · see citing works
Hurley, M. N., Ariff, A., & Smyth, A. R. (2011) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(11)60113-6 · Cited by 1 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
The Microbiome and the Respiratory Tract
Dickson, R. P., Erb-Downward, J. R., Martinez, F. J., & Huffnagle, G. B. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105238 · Cited by 953 · see citing works
The role of the microbiome in exacerbations of chronic lung diseases
Dickson, R. P., Martinez, F. J., & Huffnagle, G. B. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61136-3 · Cited by 495 · see citing works
The microbiome and critical illness
Dickson, R. P. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00427-0 · Cited by 460 · see citing works
The Lung Microbiome, Immunity, and the Pathogenesis of Chronic Lung Disease
O’Dwyer, D. N., Dickson, R. P., & Moore, B. B. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600279 · Cited by 362 · see citing works
- Authors
- Hurley, M. N., Ariff, A. H. A., Bertenshaw, C., Bhatt, J., & Smyth, A. R.
- Affiliations
- University of Nottingham (GB)
- Queen's Medical Centre (GB)
- Corresponding author
- Hurley, M.N.
- Venue
- Journal of Cystic Fibrosis
- Publisher
- Elsevier BV
- Published
- 2012-07
- Volume
- 11
- Issue
- 4
- Pages
- 288-292
- ISSN
- 1569-1993 (ISSN-L)
- PMC
- PMC3382712
- OpenAlex
- W2102376874
- Cited by
- 122
- References
- 18
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 7 · 2023: 7 · 2022: 11 · 2021: 8 · 2020: 9 · 2019: 10 · 2018: 9 · 2017: 11 · 2016: 10 · 2015: 13 · 2014: 9 · 2013: 7 · 2012: 3
- FWCI
- 8.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Cystic Fibrosis (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Nottingham ePrints (University of Nottingham) (submittedVersion, cc-by)
- Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
- Repository@Nottingham (University of Nottingham) (submittedVersion, other-oa)
- Funders
- Wellcome Trust (WT092295AIA)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Antibiotic Use and Resistance
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
- Keywords
- antimicrobial susceptibility testing, Pseudomonas aeruginosa, pulmonary exacerbations, empirical antibiotic therapy, antibiotic prescribing, antimicrobial resistance, clinical outcomes, children, FEV1, body mass index
- MeSH terms
- Adolescent, Child, Child, Preschool, Cystic Fibrosis, Female, Forced Expiratory Volume, Humans, Infant, Male, Microbial Sensitivity Tests, Pseudomonas aeruginosa, Pseudomonas Infections, Retrospective Studies, Body Mass Index, Treatment Outcome, Pneumonia, Bacterial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
